NCT05672043 Genetic and Molecular Risk Profiles of Pediatric Malignant Brain Tumors in China
| NCT ID | NCT05672043 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Beijing Tiantan Hospital |
| Condition | Medulloblastoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 400 participants |
| Start Date | 2023-01-01 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 400 participants in total. It began in 2023-01-01 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Primary malignant central nervous system (CNS) tumors are the second most common childhood malignancies. Amongst, medulloblastomas are the most common malignant brain tumor of childhood and occur primarily in the cerebellum. According to molecular characteristics, medulloblastomas were classified into four subtypes: WNT, SHH, Group3 and Group4 and different prognosis were noticed between subgroups. Several genetic predispositions related to clinical outcome were also discovered and might influence the treatment of medulloblastomas as novel pharmaceutical targets. This study aims to investigate genetic and cellular profiles of pediatric brain malignancies, mostly medulloblastomas, and other central nervous system tumor based on WGS, RNA-seq, single-cell sequencing and spatial transcriptomics. We also aim to investigate the correlation between genetic characteristics and clinical prognosis.
Eligibility Criteria
Inclusion Criteria: \- Children and adolescents aged between 0-18 years old, diagnosed with medulloblastoma or other malignant central nervous system tumors including glioma, ependymoma, germ cell tumors,tuberous sclerosis, neuronal and neuronoglial tumors, choroid plexus tumors, atypical teratoid/rhabdoid tumors, ependymoblastoma, and medulloepithelioma; Patients must be eligible for and receive tumor resection; Histological examination by institutional neuro-pathological evaluation must confirmed the diagnosis of brain malignancies; Participants consent with joining the current study and comply with follow-up visits; The patients must have no previous radiotherapy or chemotherapy other than corticosteroids. Exclusion Criteria: \- Patients with major perioperative complications which lead to significant and sudden deterioration; Patients with major systemic illness (e.g., serious infection or significant cardiac, pulmonary, hepatic, or other organ dysfunction) which might compromise the patient's ability to tolerate standard treatment or would likely interfere with overall prognosis; Patients with major adverse events or sudden deterioration irrelevant to the current study; Quality of tumor tissue sample did not meet the criterion for genetic sequencing and laboratory investigations; Patients who refuse to participate in the study or who request dropping out from the study
Contact & Investigator
Tao Jiang, MD
PRINCIPAL INVESTIGATOR
Beijing Tiantan Hospital
Frequently Asked Questions
Who can join the NCT05672043 clinical trial?
This trial is open to participants of all sexes, aged 0 Years or older, up to 18 Years, studying Medulloblastoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05672043 currently recruiting?
Yes, NCT05672043 is actively recruiting participants. Contact the research team at doctorjiangtt@163.com for enrollment information.
Where is the NCT05672043 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT05672043 clinical trial?
NCT05672043 is sponsored by Beijing Tiantan Hospital. The principal investigator is Tao Jiang, MD at Beijing Tiantan Hospital. The trial plans to enroll 400 participants.